Bhavana Bhatnagar is an Oncology physician affiliated with West Virginia University. OpenAlex indexes 182 publications with 2,781 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
40 Medical Park Ste 300
Wheeling, WV 260036392
Telephone
304-243-3715Provider last certified this registry record 8 Dec 2022.
Clinical trials
- Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
Sponsor: Bhavana Bhatnagar
- Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: Bhavana Bhatnagar
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20257 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.3%Kinase inhibitor15.1%Calquence47%Imatinib Mesylate26%Jakafi15%Bosulif11%Part D<11 patientsThalidomide Analog15.1%Lenalidomide43%Revlimid32%Pomalyst25%Part D<11 patients+ 2 more classes in this area
Dermatology
12.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.2%Acyclovir100%Part D≥18 patientsMetabolism & gastrointestinal
12.2%Corticosteroid7%Prednisone100%Part D≥18 patientsSerotonin-3 Receptor Antagonist5.3%Ondansetron Hcl100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine
2024 - Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia
Leukemia & lymphoma/Leukemia and lymphoma
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Konrad, MD, PhD
West Virginia University
Hassan Ramadan, MD
West Virginia University
Ashkan Emadi, MD, PhD
West Virginia University
George Sokos, DO
West Virginia University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”